These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15632035)

  • 1. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
    Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
    J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.
    Lambert B; Bacher K; De Keukeleire K; Smeets P; Colle I; Jeong JM; Thierens H; Troisi R; De Vos F; Van de Wiele C
    J Nucl Med; 2005 Aug; 46(8):1326-32. PubMed ID: 16085590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.
    Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
    J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model.
    Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC
    J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases.
    Liepe K; Kotzerke J; Lambert B
    J Nucl Med; 2005 Aug; 46(8):1407-8; author reply 1407-8. PubMed ID: 16085601
    [No Abstract]   [Full Text] [Related]  

  • 7. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma.
    Shinto AS; Karuppusamy KK; Kurup RER; Pandiyan A; Jayaraj AV
    Nucl Med Commun; 2021 Jan; 42(1):43-50. PubMed ID: 32956248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.
    Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP
    Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol.
    Lee YS; Jeong JM; Kim YJ; Chang YS; Lee HJ; Son M; Lee JW; Yoon HS; Kang WJ; Lee DS; Chung JK; Lee MC; Suh YG
    Appl Radiat Isot; 2007 Jan; 65(1):64-9. PubMed ID: 17010628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
    Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
    Bernal P; Raoul JL; Stare J; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Vidmar G; Buscombe J; Chau TT; Saw MM; Chen S; Ogbac R; Dondi M; Padhy AK
    Semin Nucl Med; 2008 Mar; 38(2):S40-5. PubMed ID: 18243842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.
    Bernal P; Raoul JL; Vidmar G; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Stare J; Buscombe J; Minh CT; Saw MM; Chen S; Ogbac R; Padhy AK
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1448-55. PubMed ID: 17692473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection.
    Luo TY; Hsieh BT; Wang SJ; Lin WY; Lee TW; Shen LH; Su MJ
    Nucl Med Biol; 2004 Jul; 31(5):671-7. PubMed ID: 15219287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
    Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
    Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil.
    Kumar A; Srivastava DN; Bal C
    J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary?
    Bacher K; Brans B; Monsieurs M; De Winter F; Dierckx RA; Thierens H
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1311-6. PubMed ID: 12271412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma.
    Meléndez-Alafort L; Nadali A; Zangoni E; Banzato A; Rondina M; Rosato A; Mazzi U
    Nucl Med Biol; 2009 Aug; 36(6):693-701. PubMed ID: 19647176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.
    Boschi A; Uccelli L; Duatti A; Colamussi P; Cittanti C; Filice A; Rose AH; Martindale AA; Claringbold PG; Kearney D; Galeotti R; Turner JH; Giganti M
    Nucl Med Commun; 2004 Jul; 25(7):691-9. PubMed ID: 15208496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.